PRPO
Precipio, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$26.62
+1.92%Year over year
Reported trailing growth
- Revenue
- +33.5%
- EBITDA
- +364.5%
- EBIT
- +40.9%
- EPS
- +46.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -67.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +36.7%
- EBITDA
- +154.1%
- EBIT
- +71.5%
- Net income
- +91.5%
- EPS
- +92.2%
- Free cash flow
- +66.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026